Effects of immune cells in mediating the relationship between gut microbiota and myelodysplastic syndrome: a bidirectional two-sample, two-step Mendelian randomization study
Authors (first, second and last of 5)
Collection
Advances in Immunity and Immunotherapy for Blood Cancers
This Collection on "Advances in Immunity and Immunotherapy for Blood Cancers" aims to provide a comprehensive overview of the latest breakthroughs and novel approaches in the field of immunotherapy specifically tailored for the treatment of blood cancers. The Collection seeks to explore the mechanisms of action, clinical efficacy, and safety profiles of these innovative approaches. Blood cancers, including leukemia, lymphoma, and myeloma, are a diverse group of diseases that pose significant challenges in terms of treatment options and patient outcomes. Over the past decade, there have been remarkable advancements in the development and application of immunotherapeutic strategies for blood cancers.
We welcome submissions that cover a wide range of topics, including but not limited to immune checkpoint inhibitors, CAR T cell therapy, bispecific antibodies, adoptive cell therapies, and novel immunotherapeutic targets. Authors are also encouraged to submit manuscripts that address challenges in the field, such as resistance to immunotherapy and strategies to overcome it. Additionally, the Collection welcomes submissions that explore combination therapies, personalized treatment approaches, and advancements in understanding the immune microenvironment in blood cancers.
Keywords: cancer immunity, immunotherapy, blood cancers
Editors
-
Jianxun Jim Song
Professor, Texas A&M University Health Science Center, United States.
Dr. Jianxun Jim Song is a full professor in the Department of Microbial Pathogenesis and Immunology at the Texas A&M University Health Science Center in the United States. As a Principal Investigator on various university, foundation, and NIH-funded grants, he played a pivotal role in advancing the understanding of T lymphocytes derived from pluripotent stem cells (PSC). Notably, Dr. Song's laboratory achieved a groundbreaking milestone by demonstrating the differentiation of induced PSC into functional T cells, opening new avenues for cell-based therapies.
